BioNTech SE (BNTX) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in BioNTech (BNTX) by buying shares or fractional shares at any major US broker, through a biotech or healthcare ETF that holds it, or as one holding in a thematic basket. BNTX is the US-listed American Depositary Receipt (ADR) of BioNTech SE, a German biotechnology company based in Mainz, so buying it gives you exposure to a foreign business through a security that trades in dollars on Nasdaq. BioNTech is best known as Pfizer's partner on the Comirnaty mRNA COVID-19 vaccine, but its investment story has shifted decisively toward oncology. The single most important thing to understand is that this is a transition story: declining COVID revenue funds a large, still-unproven cancer pipeline, so the thesis rests on whether its oncology programs, led by the PD-L1 x VEGF-A bispecific pumitamig, can turn a cash-rich vaccine maker into a durable cancer-drug company.
BNTX stock price
As of 2026-07-14, BioNTech SE (BNTX) last closed at $90.64, down 18.3% over the past year. Over the past 52 weeks it has traded between $83.89 and $119.34.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or BioNTech SE's investor relations page. Walnut is informational, not investment advice.
What does BioNTech SE (BNTX) do?
BioNTech SE is a German biotechnology company, headquartered in Mainz, whose shares trade in the US as an American Depositary Receipt under the ticker BNTX on Nasdaq. It rose to global prominence by co-developing the Comirnaty mRNA COVID-19 vaccine with Pfizer, which generated enormous revenue and a large cash pile at the pandemic's peak. As COVID vaccine demand has normalized, that revenue has fallen sharply, and the company has guided to substantially lower sales than the pandemic years. The investment case has therefore moved away from vaccines and toward whether BioNTech can convert its mRNA and immunotherapy platforms, and its balance sheet, into an oncology franchise.
The centerpiece of that pivot is oncology. BioNTech has more than doubled its late-stage cancer trials, running more than 25 Phase 2 or 3 programs across immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. Its lead asset is pumitamig (also known as BNT327), a bispecific antibody targeting PD-L1 and VEGF-A, being studied in lung, breast, colorectal, and other solid tumors. In 2025 BioNTech signed a global co-development and co-commercialization partnership with Bristol Myers Squibb on this program, featuring a large upfront payment and a 50/50 profit split, which both validated the asset and strengthened an already sizable cash position reported in the billions of euros. Two other facts shape the story: the company still reports net losses as it invests in R&D, and co-founders Ugur Sahin and Ozlem Tureci announced plans to leave by the end of 2026 to start a new mRNA venture, with BioNTech contributing selected mRNA rights in exchange for a minority stake.
What's driving BioNTech SE (BNTX)?
1. Oncology pipeline and pumitamig
BioNTech's future value hinges largely on its cancer pipeline, led by pumitamig (BNT327), a PD-L1 x VEGF-A bispecific antibody in trials across lung, breast, colorectal, and other solid tumors. The company runs more than 25 Phase 2 or 3 oncology programs spanning bispecifics, antibody-drug conjugates, and mRNA immunotherapies. Positive late-stage data could reprice the stock materially; setbacks would do the reverse.
2. Bristol Myers Squibb partnership
The 2025 global partnership with Bristol Myers Squibb to co-develop and co-commercialize pumitamig brought a large upfront payment, staged milestones, and a 50/50 profit-and-loss split. It both externally validated the lead asset and shares the cost and risk of an expensive, broad clinical program. Execution against the partnership's development plan is a key swing factor for the multi-year story.
3. Strong balance sheet funding the pivot
Years of Comirnaty profits, augmented by the BMS upfront, left BioNTech with a cash, equivalents, and securities position reported in the billions of euros. That war chest lets it fund a large R&D program, pursue deals, and absorb trial setbacks without immediate financing pressure, a meaningful advantage over cash-poor biotechs. How wisely that capital is deployed will shape long-run returns.
4. Declining COVID revenue and diversification
COVID vaccine sales have fallen well below pandemic peaks, and 2026 revenue guidance reflects that lower baseline. The company is working to diversify beyond Comirnaty into oncology and other infectious diseases, including partnered programs. The near-term financial picture is a shrinking, lumpy vaccine business funding a pipeline that will take years to mature, so results can look weak before the oncology bets play out.
What are the risks to BioNTech SE (BNTX)?
The dominant risk is clinical: most drug candidates fail, and BioNTech's valuation leans heavily on unproven oncology programs, so disappointing trial data for pumitamig or other assets could sharply cut the stock. Revenue is currently concentrated in a declining COVID vaccine franchise, making near-term results lumpy and dependent on seasonal demand and government contracts. As an ADR of a German company, holders also carry currency risk between the euro and the dollar and are exposed to non-US disclosure and tax nuances. The planned 2026 departure of co-founders Ugur Sahin and Ozlem Tureci introduces leadership-transition risk, even as the company says the pipeline continues unaffected. The company still reports net losses as it invests heavily in R&D, competition in immuno-oncology is intense, and regulatory approval timelines are long and uncertain. This is a high-risk, potentially high-reward biotech rather than a steady earner.
How is BioNTech SE (BNTX) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see BioNTech SE's investor relations page or your broker.
- Listing structure: US-listed ADR (BNTX on Nasdaq) of a German company, BioNTech SE, based in Mainz
- Revenue trend: Well below pandemic peaks; 2026 guidance points to a lower, COVID-vaccine-dependent revenue base
- Profitability: Reporting net losses as heavy R&D spending on the oncology pipeline outweighs shrinking vaccine profit
- Balance sheet: Very strong; cash, equivalents, and securities reported in the billions of euros, boosted by the Bristol Myers Squibb upfront
- Lead value driver: Oncology pipeline, especially pumitamig (BNT327), rather than current earnings
- Valuation basis: Driven by pipeline expectations and cash, not by conventional earnings multiples
Figures here are intentionally directional because BioNTech's reported results swing with lumpy COVID vaccine revenue and one-off partnership payments, which distort quarter-to-quarter comparisons. Conventional earnings multiples are of limited use for a company that is currently loss-making and valued largely on its pipeline and cash; a large slice of the market capitalization is effectively backed by its cash and securities balance. What matters most is the probability-weighted value of the oncology programs and how much cash is spent to reach it. Always verify the latest cash balance, guidance, and trial readouts before acting.
Who competes with BioNTech SE (BNTX)?
mRNA and vaccine platform peers
Moderna is the closest mRNA-platform comparison, also pivoting from COVID vaccines toward oncology and other applications, while Pfizer is both BioNTech's Comirnaty partner and a large vaccine rival. These companies compete for the same mRNA talent, manufacturing, and clinical opportunities that underpin BioNTech's platform.
Immuno-oncology and big pharma
In cancer, BioNTech competes against established immuno-oncology leaders such as Merck (Keytruda), Bristol Myers Squibb (which is also its pumitamig partner), Roche, and AstraZeneca. Chinese biotechs developing PD-L1 x VEGF bispecifics are direct rivals to pumitamig's mechanism. These players have deep pockets, marketed drugs, and large trial infrastructure.
Clinical-stage biotech peers
BioNTech also sits alongside a broad field of clinical-stage biotechs advancing antibody-drug conjugates, bispecifics, and cell therapies. They offer investors alternative, similarly binary ways to bet on oncology innovation, though few match BioNTech's cash cushion or its validating big-pharma partnership.
How to invest in BioNTech SE (BNTX)
There are three common ways to get BNTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so BNTX sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where BNTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on BioNTech SE (BNTX)
BioNTech is a cash-rich German biotech, US-listed as an ADR, pivoting from fading COVID vaccine revenue to a broad oncology pipeline anchored by the Bristol Myers Squibb-partnered bispecific pumitamig. It rewards belief in clinical success and punishes trial setbacks; the question is your tolerance for binary drug-development risk.
Build a basket around BNTX with Walnut
Use BioNTech SE as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is BNTX a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a cash-rich company with a validated, Bristol Myers Squibb-partnered lead cancer asset and a deep oncology pipeline that could reprice the stock if trials succeed. The bear case is that COVID revenue is falling, the company is loss-making, most drug candidates fail, and a founder transition is underway. BNTX is a high-risk, pipeline-driven biotech; weigh that volatility against your portfolio.
Is BNTX a US or foreign stock?
+
BioNTech SE is a German company headquartered in Mainz, but it trades in the US as an American Depositary Receipt (ADR) under the ticker BNTX on Nasdaq. That means you buy a dollar-denominated security representing shares of the foreign company. As an ADR holder you take on currency risk between the euro and the dollar and some non-US tax and disclosure nuances.
What does BioNTech actually do?
+
BioNTech is a biotechnology company that develops immunotherapies and vaccines using mRNA and other platforms. It co-developed the Comirnaty COVID-19 vaccine with Pfizer, and it is now focused heavily on oncology, running more than 25 late-stage cancer trials across bispecific antibodies, antibody-drug conjugates, and mRNA cancer immunotherapies, alongside other infectious-disease work.
What is pumitamig (BNT327)?
+
Pumitamig, also known as BNT327, is BioNTech's lead oncology candidate: a bispecific antibody that targets both PD-L1 and VEGF-A. It is being studied across solid tumors including lung, breast, and colorectal cancers. In 2025 BioNTech partnered with Bristol Myers Squibb to co-develop and co-commercialize it, which is why data readouts on this program are closely watched.
How does the Bristol Myers Squibb partnership work?
+
In 2025 BioNTech and Bristol Myers Squibb agreed to co-develop and co-commercialize pumitamig globally, with a large upfront payment to BioNTech, additional staged payments and milestones, and a 50/50 split of profits and losses. The deal validated the asset externally, shared the heavy cost of a broad clinical program, and strengthened BioNTech's already large cash position.
Why is BioNTech still losing money?
+
COVID vaccine revenue has fallen well below pandemic peaks, while the company invests heavily in research and development to build its oncology pipeline. That combination of a shrinking revenue base and large R&D spending produces net losses. The strategy is to spend now, funded by its cash pile, in hopes that successful cancer drugs generate profits later; there is no guarantee they will.
What does the founder departure mean for the stock?
+
Co-founders Ugur Sahin and Ozlem Tureci announced plans to leave BioNTech by the end of 2026 to start a new mRNA-focused company, with BioNTech contributing selected mRNA rights in exchange for a minority stake. The company says its existing oncology and infectious-disease pipeline continues unaffected, but any transition of scientific leadership adds a layer of uncertainty for investors to weigh.
How can I get exposure to BNTX through an ETF?
+
BNTX appears in many biotechnology and broad healthcare ETFs, where it sits among mid-to-large biotech names. ETF exposure spreads single-stock, binary trial risk across many holdings, but it dilutes how much any BioNTech move affects you. Check a fund's holdings and weighting before assuming meaningful exposure to BioNTech specifically.
What are the main risks of investing in BNTX?
+
The biggest risk is clinical failure: the stock leans on unproven cancer programs, and most drug candidates do not succeed, so weak trial data could hit it hard. Revenue is concentrated in a declining COVID vaccine franchise, making results lumpy. As an ADR there is euro-dollar currency risk, the company is currently loss-making, immuno-oncology competition is fierce, and a founder transition is underway. It is a high-risk, high-reward biotech.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with BioNTech SE's investor relations page or your broker before making investment decisions.